See the DrugPatentWatch profile for Nateglinide
Can you estimate the cost to build a Nateglinide (Starlix) manufacturing plant?
No reliable, public figure exists for the total “manufacturing plant cost” for Nateglinide marketed as Starlix. The available information is typically kept internal by manufacturers, and plant investment can vary widely based on capacity (kg/year), process route, solvent recovery, utilities, cleanroom or containment requirements, and whether it’s new-build vs. retrofit.
What makes Nateglinide/Starlix plant costs swing so much?
Even for the same active ingredient, reported capital costs for APIs (active pharmaceutical ingredients) can differ due to:
- Manufacturing scope: API only vs. API + formulation/packaging.
- Scale and output: small pilot-scale vs. high-throughput commercial lines.
- Facility type: bulk chemical/API equipment vs. GMP solid dosage manufacturing.
- Regulatory and engineering requirements: multipurpose GMP suites, containment, emissions treatment, and validation scope.
- Supply-chain setup: number of synthesis steps, in-house vs. outsourced intermediates, and solvent/impurity handling.
If someone is budgeting, what inputs do they usually use?
When companies or engineering firms estimate API plant CAPEX, they typically start from:
- Target annual capacity (kg/year) and batch size
- Process cycle time and number of campaigns per year
- Raw materials and reagents handling assumptions (especially hazardous/regulated solvents)
- Utilities requirements (steam, chilled water, compressed air, HVAC, purified water)
- Utilities and compliance systems (wastewater, off-gas scrubbers, solvent recovery)
- Quality systems and validation effort for GMP operation
Are there public cost benchmarks for API plants?
General industry benchmarks exist for “chemical plant” and “pharma GMP facility” CAPEX, but they are not specific to Nateglinide or to Starlix. Without Nateglinide-specific design data (capacity and facility scope), applying generic benchmarks would produce a weak, non-actionable estimate.
What would let me give you a more concrete number?
If you share any of the following, I can narrow the estimate approach (still without claiming Starlix-specific facts):
- Do you mean API manufacturing only (nateglinide) or also tablets (Starlix formulation)?
- Target capacity (e.g., 1 ton/year, 5 tons/year, etc.)
- Region/standard (EU cGMP, US cGMP, etc.)
- New plant vs. expansion/upgrade
- Desired timeline (design/build)
If you confirm those details, I can translate them into a realistic budgeting range based on typical API vs. dosage manufacturing facility cost drivers.
Sources
No sources were provided with your question, and there are no Nateglinide/Starlix plant-cost figures included in the information available to me here.